Efficacy of Rituximab Combined with Plasma Exchange in the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

Abstract

Objective: To analyze the curative effect of rituximab combined with plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Methods: 70 patients with thrombotic thrombocytopenic purpura that were treated in our hospital from January 2022 to January 2023 were selected for this study. They were divided into two groups according the treatment method they were about to receive. The patients in the control group received plasma exchange. The observation group was given rituximab in addition to plasma exchange. Then, the therapeutic effects of the two groups were observed, and the incidence of adverse reactions was compared. Results: The rate of effectiveness of the treatment received in observation group and the control group was 97.14% and 82.86%, respectively. The treatment received in observation group had a better therapeutic effect (P < 0.05). The incidence of adverse reactions in the observation group (22.86%) was lower than that of the control group (5.71%) , with P < 0.05. Conclusion: Rituximab combined with plasma exchange is relatively more effective than plasma exchange alone, with less adverse reaction, making it a viable treatment option.